BioVie's bezisterim shows Phase 2 gains in Parkinson's trial

August 6, 2026 7:30 AM

BioVie Inc. (NASDAQ: BIVI) reported topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson's disease, with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found